| 1 |
34937948 | Correction: Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signaling. | 2022 Mar |
1 |
| 2 |
34964241 | Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy. | 2022 Feb |
1 |
| 3 |
35053532 | Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin. | 2022 Jan 12 |
1 |
| 4 |
35144430 | Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature. | 2022 Jan |
1 |
| 5 |
32705436 | HIF1α and p53 Regulated MED30, a Mediator Complex Subunit, is Involved in Regulation of Glioblastoma Pathogenesis and Temozolomide Resistance. | 2021 Oct |
1 |
| 6 |
33691199 | Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner. | 2021 Apr 23 |
2 |
| 7 |
34044759 | miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop. | 2021 May 27 |
2 |
| 8 |
34072831 | NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. | 2021 May 31 |
4 |
| 9 |
34253592 | Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses. | 2021 Oct |
1 |
| 10 |
34539842 | Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide. | 2021 Nov |
1 |
| 11 |
34660288 | Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53-PUMA Apoptosis Pathway. | 2021 |
3 |
| 12 |
34733363 | Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population. | 2021 Dec |
1 |
| 13 |
32296580 | Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway. | 2020 Feb 15 |
1 |
| 14 |
32666844 | Evaluation of frequency magnetic field, static field, and Temozolomide on viability, free radical production and gene expression (p53) in the human glioblastoma cell line (A172). | 2020 Oct 1 |
4 |
| 15 |
32785787 | Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report. | 2020 Dec |
2 |
| 16 |
32878802 | Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells. | 2020 Sep |
2 |
| 17 |
30361254 | Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB. | 2019 Jan 1 |
1 |
| 18 |
30536898 | Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. | 2019 Jun 15 |
1 |
| 19 |
30664150 | Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy. | 2019 Mar |
1 |
| 20 |
30796178 | The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death. | 2019 May |
5 |
| 21 |
30925722 | Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? | 2019 Mar 28 |
1 |
| 22 |
30940658 | Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma. | 2019 May 15 |
3 |
| 23 |
31081046 | Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. | 2019 Jun |
3 |
| 24 |
31190889 | Artificial microenvironment of in vitro glioblastoma cell cultures changes profile of miRNAs related to tumor drug resistance. | 2019 |
1 |
| 25 |
31534534 | MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas. | 2019 |
1 |
| 26 |
29334602 | High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy. | 2018 Oct |
1 |
| 27 |
29416795 | Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma. | 2018 Jan 5 |
4 |
| 28 |
29749471 | GSK3β‑mediated Ser156 phosphorylation modulates a BH3‑like domain in BCL2L12 during TMZ‑induced apoptosis and autophagy in glioma cells. | 2018 Aug |
4 |
| 29 |
30050935 | Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest. | 2018 |
3 |
| 30 |
27177180 | Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist. | 2017 Feb |
2 |
| 31 |
27651340 | The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. | 2017 |
1 |
| 32 |
27888811 | The role of p53 in cancer drug resistance and targeted chemotherapy. | 2017 Jan 31 |
1 |
| 33 |
28147244 | The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines. | 2017 Mar 27 |
1 |
| 34 |
28232952 | Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. | 2017 |
1 |
| 35 |
28427200 | IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. | 2017 Apr 25 |
1 |
| 36 |
28726196 | Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide. | 2017 Jun |
1 |
| 37 |
28821714 | GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. | 2017 Aug 18 |
3 |
| 38 |
26498391 | Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation. | 2016 Jan |
1 |
| 39 |
27777210 | [RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells]. | 2016 Oct 20 |
1 |
| 40 |
28000777 | BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53. | 2016 Dec 21 |
3 |
| 41 |
25240597 | A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. | 2015 Feb |
3 |
| 42 |
25625235 | p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. | 2015 Jun |
2 |
| 43 |
25681668 | The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. | 2015 May 1 |
3 |
| 44 |
25808868 | Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide. | 2015 May 15 |
1 |
| 45 |
26428461 | A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. | 2015 Nov 28 |
1 |
| 46 |
26553592 | MIR517C inhibits autophagy and the epithelial-to-mesenchymal (-like) transition phenotype in human glioblastoma through KPNA2-dependent disruption of TP53 nuclear translocation. | 2015 |
2 |
| 47 |
26904387 | Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics. | 2015 Dec |
1 |
| 48 |
24248532 | Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. | 2014 Apr |
4 |
| 49 |
24453002 | Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. | 2014 Mar 15 |
1 |
| 50 |
24647572 | ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. | 2014 May 15 |
1 |